Zhang C - Search Results

1

[Response and prognosis of patients with multiple myeloma induced by PAD/TAD].

Zeng T, He H, Shi H, Xi H, Du J, Zhang C, Jiang H, Fu W, Zhou F, Hou J. Zeng T, et al. Among authors: zhang c. Zhonghua Yi Xue Za Zhi. 2015 Mar 17;95(10):731-5. Zhonghua Yi Xue Za Zhi. 2015. PMID: 26080842 Chinese.

2

Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.

Huang H, Zhou L, Peng L, Fu W, Zhang C, Hou J. Huang H, et al. Among authors: zhang c. Leuk Res. 2014 Sep;38(9):1048-54. doi: 10.1016/j.leukres.2014.06.009. Epub 2014 Jun 30. Leuk Res. 2014. PMID: 25052306

3

Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapy.

Zeng T, Zhou L, Xi H, Fu W, Du J, Zhang C, Jiang H, Hou J. Zeng T, et al. Among authors: zhang c. Stem Cells Int. 2015;2015:613045. doi: 10.1155/2015/613045. Epub 2015 Jan 22. Stem Cells Int. 2015. PMID: 25688273 Free PMC article.

4

The clinical characteristics and prognosis of IGH deletion in multiple myeloma.

He H, Fu W, Jiang H, Du J, Zhou L, Zhang C, Xi H, Li R, Hou J. He H, et al. Among authors: zhang c. Leuk Res. 2015 May;39(5):515-9. doi: 10.1016/j.leukres.2015.02.010. Epub 2015 Mar 18. Leuk Res. 2015. PMID: 25817540

5

[Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].

Jin L, Fu W, Xi H, Zhang C, Du J, He H, Jiang H, Zeng T, Fan J, Zhou L, Chang H, Hou J. Jin L, et al. Among authors: zhang c. Zhonghua Xue Ye Xue Za Zhi. 2016 Jan;37(1):14-9. doi: 10.3760/cma.j.issn.0253-2727.2016.01.003. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 26876247 Free PMC article. Chinese.

6

[Exploration of early assessment of renal impairment in multiple myeloma].

Zhong Y, Yuan ZG, Fu WJ, Zhou F, Zhang CY, Zhang WH, Hou J. Zhong Y, et al. Zhonghua Xue Ye Xue Za Zhi. 2012 Oct;33(10):819-22. Zhonghua Xue Ye Xue Za Zhi. 2012. PMID: 23384902 Chinese.

7

[The efficacy and safety analysis of bortezomib retreatment in 76 patients with relapsed/refractory multiple myeloma].

Lu J, Hou J, Zhang CY, Yuan ZG, Lan HF, Zhou F, Fan JL, Zhou LL, Du J, Jiang H, Jin LN, Zeng TM, Fu WJ. Lu J, et al. Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):309-12. doi: 10.3760/cma.j.issn.0253-2727.2013.04.013. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23668202 Chinese.

8

[Busulfan, cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma].

Zhang CY, Fu WJ, Xi H, Zhou LL, Jiang H, Du J, Fan JL, Li R, Jin LN, Zeng TM, Hou J. Zhang CY, et al. Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):313-6. doi: 10.3760/cma.j.issn.0253-2727.2013.04.014. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23668203 Chinese.

9

[Clinical and laboratory features of four cases with IgM multiple myeloma].

Fan JL, Fu WJ, Shi HT, Zhou F, Yuan ZG, Zhang CY, Wei W, Ye F, Zhang H, Hou J. Fan JL, et al. Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):341-4. doi: 10.3760/cma.j.issn.0253-2727.2013.04.020. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23668209 Chinese.

10

[The clinical characteristics and prognostic analysis of 147 cases of diffuse large B-cell lymphoma].

Zhao Q, Fu WJ, Zhang CY, Du J, Xi H, Hou J. Zhao Q, et al. Zhonghua Xue Ye Xue Za Zhi. 2013 Sep;34(9):737-40. doi: 10.3760/cma.j.issn.0253-2727.2013.09.001. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 24103868 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75,499 results

Search Page

Filters